Cellectis (ALCLS) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.139x

Based on the latest financial reports, Cellectis (ALCLS) has a cash flow conversion efficiency ratio of -0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.58 Million ≈ $-12.37 Million USD) by net assets (€75.91 Million ≈ $88.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALCLS days of operational coverage to measure how many days the company can operate on defensive assets alone.

Cellectis - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Cellectis's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cellectis Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellectis ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Vecima Networks Inc. TO:VCM	0.092x
Runway Growth Finance Corp NASDAQ:RWAY	0.009x
Peña Verde S.A.B MX:PV	0.005x
Adagene Inc NASDAQ:ADAG	-0.129x
Caxton JSE:CAT	0.109x
Mandala Multifinance Tbk JK:MFIN	-0.027x
Z.M.H Hammerman Ltd TA:ZMH	-0.103x
Journey Energy Inc TO:JOY	0.041x

Annual Cash Flow Conversion Efficiency for Cellectis (2005–2025)

The table below shows the annual cash flow conversion efficiency of Cellectis from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see ALCLS market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€75.91 Million ≈ $88.75 Million	€-41.64 Million ≈ $-48.69 Million	-0.549x	-412.69%
2024-12-31	€131.03 Million ≈ $153.19 Million	€22.99 Million ≈ $26.88 Million	0.175x	+160.05%
2023-12-31	€84.69 Million ≈ $99.02 Million	€-24.75 Million ≈ $-28.93 Million	-0.292x	+57.92%
2022-12-31	€125.94 Million ≈ $147.24 Million	€-87.44 Million ≈ $-102.23 Million	-0.694x	-57.03%
2021-12-31	€236.47 Million ≈ $276.46 Million	€-104.56 Million ≈ $-122.24 Million	-0.442x	-70.15%
2020-12-31	€308.85 Million ≈ $361.07 Million	€-80.26 Million ≈ $-93.83 Million	-0.260x	-33.61%
2019-12-31	€355.47 Million ≈ $415.58 Million	€-69.14 Million ≈ $-80.83 Million	-0.195x	-28.54%
2018-12-31	€450.27 Million ≈ $526.41 Million	€-68.14 Million ≈ $-79.66 Million	-0.151x	+17.32%
2017-12-31	€285.90 Million ≈ $334.25 Million	€-52.33 Million ≈ $-61.18 Million	-0.183x	-61.34%
2016-12-31	€274.05 Million ≈ $320.39 Million	€-31.09 Million ≈ $-36.34 Million	-0.113x	-1024.12%
2015-12-31	€288.22 Million ≈ $336.95 Million	€3.54 Million ≈ $4.14 Million	0.012x	-98.25%
2014-12-31	€72.39 Million ≈ $84.63 Million	€50.74 Million ≈ $59.32 Million	0.701x	+118.19%
2013-12-31	€6.65 Million ≈ $7.77 Million	€-25.63 Million ≈ $-29.96 Million	-3.854x	-1105.67%
2012-12-31	€81.69 Million ≈ $95.50 Million	€-26.11 Million ≈ $-30.53 Million	-0.320x	+10.29%
2011-12-31	€37.02 Million ≈ $43.28 Million	€-13.19 Million ≈ $-15.42 Million	-0.356x	+15.35%
2010-12-31	€50.13 Million ≈ $58.60 Million	€-21.10 Million ≈ $-24.67 Million	-0.421x	-337.25%
2009-12-31	€73.22 Million ≈ $85.60 Million	€-7.05 Million ≈ $-8.24 Million	-0.096x	-350.06%
2008-12-31	€46.21 Million ≈ $54.03 Million	€1.78 Million ≈ $2.08 Million	0.038x	+129.82%
2007-12-31	€43.54 Million ≈ $50.91 Million	€-5.62 Million ≈ $-6.57 Million	-0.129x	-400.76%
2005-12-31	€9.11 Million ≈ $10.65 Million	€391.00K ≈ $457.12K	0.043x	--

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$233.04 Million

€199.33 Million EUR

Market Cap Rank

#16044 Global

#234 in France

Share Price

€2.75

Change (1 day)

+2.08%

52-Week Range

€1.23 - €4.57

All Time High

€40.90